Glioblastoma Multiforme: Global Drug Forecast and Market Analysis to 2030
All the vital news, analysis, and commentary curated by our industry experts.
Glioblastoma multiforme (GBM) is now defined by the WHO 2021 as a diffuse astrocytic glioma with no mutations in IDH genes or histone H3 genes. It is the most common primary brain tumor in humans. Like other astrocytomas, GBM originates from astrocytes, a type of glial cells that are non-neuronal and function to provide structural and biochemical support to the brain’s neuronal network. GBM continues to be a disease with some of the highest unmet needs in oncology, with patients having a median overall survival (OS) of between one and two years. The lack of therapies is primarily due to the inability of drugs to penetrate the blood-brain barrier (BBB).
The market of GBM relies predominantly on temozolomide and bevacizumab, which accounted for 46% and 51%, respectively, of the total $549.1M sales in 2020. For this market to witness true growth, the currently marketed products would need to be almost entirely replaced by new pipeline products, owing to the significant presence of generic temozolomide and the introduction of bevacizumab biosimilars. However, a high failure rate has been historically observed for late-stage GBM trials and may impact the pipeline forecast and impede the market growth. Nevertheless, eight pipeline agents are expected to enter the 8MM and drive the GBM growth to $868.5M by 2030 at a Compound Annual Growth Rate (CAGR) of 4.7%.
KEY QUESTIONS ANSWERED
Eight Phase II-III pipeline agents are expected to enter the Glioblastoma market from 2024 onwards. What impact will these agents have on the market? Which of these drugs will have the highest peak sales, and why?
What are the current unmet needs in GBM, which pipeline agents are positioned to counter these unmet needs? What are the opportunities for R&D?
What are the current research and development (R&D) strategies being explored and how can developers incorporate these methods into their business strategy?
What is the expected future uptake of protein kinase inhibitors across the 8MM?
Overview of Glioblastoma Multiforme including epidemiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
Topline Glioblastoma Multiforme market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.
Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting Glioblastoma Multiforme therapeutics sales in the 8MM.
Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs (Phase II – III).
Analysis of the current and future market competition in the global Glioblastoma Multiforme therapeutics market. Insightful review of the key industry drivers and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
The main drivers of growth include the anticipated approval and launch of eight pipeline agents during the forecast period, of which cancer vaccines and protein kinase inhibitors are the dominating classes.
The primary barrier to growth in the forecast period will be the high failure rates historically observed for Phase III GBM trials, impacting the pipeline forecast. The high genericization of temozolomide and recent patent expiration of Avastin, leading to biosimilar entry, also reduces the Glioblastoma Multiforme (GBM) market potential.
DCVax-L, regorafenib, and paxalisib are the three pipeline agents expected to generate the highest sales for GBM from 2020-2030.
Aside from improving OS, other key unmet needs in the GBM market include; Predictive biomarkers to guide personalized therapy and the need to find more efficacious treatment in O6-methylguanine-DNA methyltransferase (MGMT) unmethylated patients who typically have a poor response to temozolomide.
Reasons to Buy
The report will enable you to:
Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
Develop business strategies by understanding the trends shaping and driving the global Glioblastoma Multiforme therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Glioblastoma Multiforme market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Track drug sales in the global Glioblastoma Multiforme therapeutics market from 2020-2030.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Merck & Co
Heritage Pharmaceuticals (Emcure)
Nipro ES Pharma
Epitopoietic Research Corporation
Table of Contents
| List of Tables
| List of Figures
| About GlobalData
1 Glioblastoma Multiforme: Executive Summary
1.1 The Glioblastoma Multiforme Market is Forecast to Reach $868.5M by 2030 Across the 8MM
1.2 GBM-AGILE Candidates Set to Penetrate the Market While Merck & Co. Expands its Early-Stage Portfolio and Roche Experiences Erosion
1.3 High Unmet Needs Exist in the GBM Market, Especially in MGMT-Promoter Unmethylated Patients and Unresectable Patients
1.4 Opportunities for New Entrants with Better Markers of Prognosis and Drug Targets
1.5 Novel GBM-AGILE Drug Candidates and Immunotherapies Expected to Launch During the Forecast Period
1.6 What Do Physicians Think?
2.2 Related Reports
2.3 Upcoming Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.2 Classification or Staging Systems
4.1 Disease Background
4.2 Risk Factors and Comorbidities
4.3 Global and Historical Trends
4.4 8MM Forecast Methodology
4.4.2 Forecast Assumptions and Methods
4.4.3 Diagnosed Incident Cases of Brain Cancer
4.4.4 Diagnosed Incident Cases of Brain Cancer by Type
4.4.5 Diagnosed Incident Cases of Glioblastoma by Grade
4.4.6 Diagnosed Incident Cases of Glioblastoma by Origin
4.4.7 Diagnosed Incident Cases of Glioblastoma by Biomarkers
4.4.8 Diagnosed Incident Cases of Glioblastoma by Mutations
4.4.9 Five-Year Diagnosed Prevalent Cases of Brain Cancer
4.5.1 Epidemiological Forecast Insight
4.5.2 COVID-19 Impact
4.6 Epidemiological Forecast for Brain Cancer (2020–2030)
4.6.1 Diagnosed Incident Cases of Brain Cancer
4.6.2 Age-Specific Diagnosed Incident Cases of Brain Cancer
4.6.3 Sex-Specific Diagnosed Incident Cases of Brain Cancer
4.6.4 Diagnosed Incident Cases of Brain Cancer by Type
4.6.5 Diagnosed Incident Cases of Glioblastoma by Grade
4.6.6 Diagnosed Incident Cases of Glioblastoma by Origin
4.6.7 Diagnosed Incident Cases of Glioblastoma by Biomarkers
4.6.8 Diagnosed Incident Cases of Glioblastoma by Mutations
4.6.9 Five-Year Diagnosed Prevalent Cases of Brain Cancer
4.6.10 Limitations of the Analysis
4.6.11 Strengths of the Analysis
5 Disease Management
5.1 Diagnosis and Treatment Overview
5.2 KOL Insights on Disease Management
6 Current Treatment Options
7 Unmet Needs and Opportunity Assessment
7.2 Identification and Validation of Biomarkers and Drug Targets
7.3 Overcoming the Blood-Brain Barrier to Improve the Efficacy of Treatments
7.4 Better Treatment Options for MGMT Unmethylated and Unresectable Patients
7.5 Differentiating Pseudoprogression and True Progression
9 R&D Strategies
9.1.1 The Efficacy of Immunotherapy in GBM
9.1.2 Predictive Biomarkers and Targeted Therapy
9.1.3 Improving Therapy Administration Routes
9.2 Clinical Trials Design
9.2.1 Clinical Endpoints
9.2.2 More Umbrella or Platform Trial Designs
9.2.3 Comparator Arms
10 Pipeline Assessment
10.2 Promising Drugs in Clinical Development
11 Pipeline Valuation Analysis
11.2 Competitive Assessment
12 Current and Future Players
12.2 Deal-Making Trends
13 Market Outlook
13.1 Global Markets
13.1.2 Drivers and Barriers – Global Issues
13.2.2 Key Events
13.2.3 Drivers and Barriers
13.3.2 Key Events
13.3.3 Drivers and Barriers
13.4.2 Key Events
13.4.3 Drivers and Barriers
13.5.2 Key Events
13.5.3 Drivers and Barriers
14.3.1 Forecasting Methodology
14.4 Primary Research – KOLs Interviewed for This Report
14.5 Primary Research – Prescriber Survey
14.6 About the Authors
14.6.2 Therapy Area Director
14.6.4 Managing Epidemiologist
14.6.5 Global Director of Therapy Analysis and Epidemiology
14.6.6 Global Head and EVP of Healthcare Operations and Strategy
14.1 Contact Us
Frequently asked questions
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Business Intelligence & Marketing Manager, SAL Heavy Lift
“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.
GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”
Market Analyst & Management, Liebherr-Werk
“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”
Head of Key Accounts, Saab AB
Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.
Marketing Intelligence Manager, Portugal Foods
Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.
Head of Customer Insight and Research, Standard Chartered
Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.
I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.
I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.
Head of Consumer Sensory Insights, Givaudan
“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.
Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”
Senior Account Manager, TSYS
GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise. The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.
I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.
One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.